Revenue hit $14.9 million with 29% growth; backlog reached $31 million.

Revenue surged 32.4% as 1P business and refurbished devices drove growth.

Record trading volumes and client assets surge as U.S. tech demand accelerates.

Revenue surged 561% year-over-year to $46.1 million following the Juniper merger.

Net loss narrowed to $6.3 million as operating costs fell and FDA submissions advanced.

Revenue guidance cut to $40 million–$43 million as memory costs rise and customer timelines extend.

Tokenization and debt refinancing reshape capital formation strategy.

VDR revenue surged 71% as management targets breakeven by mid-2027.

Medical education revenue grew 7% amid AI competition in clinical tools.

Revenue hit $10.7 million with 42 straight quarters of growth; EBITDA guidance was raised.

Phase 3 trials for rezpegaldesleukin advance in atopic dermatitis and alopecia areata.

Credit portfolio doubled as management navigates higher rates and defaults.

Net income hit $1.1 billion while customer base grew to 139 million.

Revenue flat as cost cuts narrowed losses and cash strengthened.

Revenue surged 99% year-over-year on HEMANGEOL relaunch and rare disease portfolio growth.